1. Iung B. Baron G., Butchart E.G.A. prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on valvular heart disease. Eur Heart J. - 2003. - Vol 24. - P. 1231 - 1243.

2. Nishimura R.A., Otto C.M., Bonow R.O., Carabello B.A., Erwin III J.P., Guyton R.A., O'Gara P.T. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease A Report of the American College of Cardiology. American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2014; 63(22): e57 - 185.

3. Otto C.M. Calcific aortic stenosis - time to look more closely at the valve. N. England J. Med 2008; 359: 1395-8.

4. Nishimura R.A., Otto C.M. Bonow R.O, Carabello B.A., Erwin J.P. III, Fleisher L.A., Jneid H. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease A Report of the American College of. Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017; 135: e1159 - e1195.

5. Baumgartner H., Hung J., Bermejo J., Chambers J.B., Edvardsen T., Goldstein S., Lancellotti P., Le Fevre M., Miller F., Otto C.M. Focus update on the echocardiographic assessment of aortic valve stenosis: EAE/ASE recommendations for clinical practice. Eur Heart J Cardiovasc Imaging 2017; 18: 254 - 275.

6. Henein M.Y. Valvular Heart Disease in Clinical Practice. Springer Science. 2010.

7. Carabello B.A. Clinical practice: aortic stenosis. N. Engl J Med 2002; 346: 677-82.

8. Irtyuga O., Babakekhyan M., Kostareva A., Uspensky V., Gordeev M., Faggian G., Malashicheva A., Metsker O., Shlyakhto E., Kopanitsa G. Analysis of Prevalence and Clinical Features of Aortic Stenosis in Patients with and without Bicuspid Aortic Valve Using Machine Learning Methods. J Pers Med. 2023 Nov 9; 13(11): 1588. doi: 10.3390/jpm13111588.

9. Иртюга О.Б., Чистякова В.И., Тенчурина А.О., Солнцев В.Н., Кушнарева Е.А., Жидулева Е.В., Малев Э.Г., Антонова И.В., Гордеев М.Л., Демченко Е.А. Частота выявления и клиническая значимость латентного инфекционного эндокардита у пациентов с аортальным стенозом. Российский кардиологический журнал. 2019; (11): 10 - 15. https://doi.org/10.15829/1560-4071-2019-11-10-15.

10. Nkomo V.T., Gardin J.M., Skelton T.N., Gottdiener J.S., Scott C.G., Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet 2006; 368: 1005-11.

11. Otto C.M., Nishimura R.A., Bonow R.O., et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2020; Dec 17; doi: 10.1161/CIR.0000000000000932. Epub 2020 Dec 17.

12. Rosenhek R., Binder T., Porenta G., Lang I., Christ G., Schemper M., Maurer G., Baumgartner H. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000; 343: 611 - 617.

13. Bergler-Klein J., Gyongyosi M., Maurer G. The role of biomarkers in valvular heart disease: focus on natriuretic peptides. Can J Cardiol 2014; 30: 1027 - 1034.106: 2224-30.

14. Baumgartner H., Falk V., Bax J.J., Bonis M., Hamm C., Per Johan Holm P.J.J., Iung B., Lancellotti P., Lansac E. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. The Task Force for the Management of Valvular Heart Diseas of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal (2017) 38, 2739 - 2791.

15. Otto C.M., Burwash I.G., Legget M.E., et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation 1997; 95: 2262-70.

16. Pellikka P.A., Sarano M.E., Nishimura R.A., et al. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation 2005; 111: 3290-5.

17. Theresa A. McDonagh, Marco Metra, Marianna Adamo, Roy S. Gardner, Andreas Baumbach, Michael , et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment, of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, Volume 42, Issue 36, 21 September 2021, Pages 3599 - 3726, https://doi.org/10.1093/eurheartj/ehab368.

18. Alec Vahanian, Friedhelm Beyersdorf, Fabien Praz, Milan Milojevic, Stephan Baldus, Johann Bauersachs, Davide Capodanno, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management, of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2021; ehab395, https://doi.org/10.1093/eurheartj/ehab395.

19. Monin J.L., Quere J.P., Monchi M., et al. Low-gradient aortic stenosis: operative risk stratification and predictors for long-term outcome: a multicenter study using dobutamine stress hemodynamics. Circulation 2003; 108: 319-24.

20. Levy F., Laurent M., Monin J.L., Maillet J.M., Pasquet A., Le Tourneau T., Petit-Eisenmann H., Gori M., Jobic Y., Bauer F., Chauvel C., Leguerrier A., Tribouilloy C. Aortic valve replacement for low-flow/low-gradient aortic stenosis operative risk stratification, and long-term outcome: a European multicenter study. J Am Coll Cardiol 2008; 51: 1466 - 1472.

21. Das P., Rimington H., Chambers J. Exercise testing to stratify risk in aortic stenosis. Eur Heart J 2005; 26:1309-13.

22. Henri C., Pierard L.A., Lancellotti P., Mongeon Р., Pibarot P., Basmadjian A.J. Exercise testing and stress imaging in valvular heart disease. Can J Cardiol 2014; 30: 1012 - 1026.

23. Azevedo C.F., Nigri M., Higuchi M.L., Pomerantzeff P.M., Spina G.S., Sampaio R.O., Tarasoutchi F., Grinberg M., Rochitte C.E. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with, severe aortic valve disease. J Am Coll Cardiol 2010; 56: 278 - 287.

24. Cueff C., Serfaty J.M., Cimadevilla C., Laissy J.P., Himbert D., Tubach F., Duval X., Iung B., Enriquez-Sarano M., Vahanian A., Messika-Zeitoun D. Measurement of aortic valve calcification using multislice computed tomography: correlation with haemodynamic, severity of aortic stenosis and clinical implication for patients with low ejection fraction. Heart 2011; 97: 721 - 726.

25. Clavel M.A., Messika-Zeitoun D., Pibarot P., Aggarwal S.R., Malouf J., Araoz P.A., Michelena H.I., Cueff C., Larose E., Capoulade R., Vahanian A., Enriquez-Sarano M. The complex nature of discordant severe calcified aortic valve disease grading: new insights from, combined Doppler echocardiographic and computed tomographic study. J Am Coll Cardiol 2013; 62: 2329 - 2338.

26. Gerber M.A., Baltimore R.S., Eaton C.B., Gewitz M., Rowley A.H., Shulman S.T., Taubert K.A. Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic, Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care, and Outcomes Research.

27. Rossebo A.B., Pedersen T.R., Boman K., Brudi P., Chambers J.B., Egstrup K., Gerdts E., Gohlke-Barwolf C., Holme I., Kesaniemi Y.A., Malbecq W., Nienaber C.A., Ray S., Skjaerpe T., Wachtell K., Willenheimer R., SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359: 1343 - 1356.

28. Bull S., Loudon M., Francis J.M., Joseph J., Gerry S., Karamitsos T.D., Prendergast B.D., Banning A.P., Neubauer S., Myerson S.G. A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial). Eur Heart J Cardiovasc Imaging 2015; 16: 834841. 249. 250.

29. Ochiai T., Saito S., Yamanaka F., Shishido K., Tanaka Y., Yamabe T., Shirai S., Tada N., Araki M., Naganuma T., Watanabe Y., Yamamoto M., Hayashida K. Reninangiotensin system blockade therapy after transcatheter aortic valve implantation. Heart 2018; 104: 644651.

30. Dahl J.S., Videbaek L., Poulsen M.K., Pellikka P.A., Veien K., Andersen L.I., Haghfelt T., Moller J.E. Effect of candesartan treatment on left ventricular remodeling after aortic valve replacement for aortic stenosis. Am J Cardiol 2010; 106: 713719.

31. Cowell S.J., Newby D.E., Prescott R.J., et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl Med 2005; 352:2 389 - 97.

32. Breithardt G., Baumgartner H., Berkowitz S.D., Hellkamp A.S., Piccini J.P., Stevens S.R., Lokhnygina Y., Patel M.R., Halperin J.L., Singer D.E., Hankey G.J., Hacke W., Becker R.C., Nessel C.C., Mahaffey K.W., Fox K.A., Califf R.M., Committee RAS, Investigators. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J 2014; 35: 3377 - 3385.

33. Avezum A., Lopes R.D., Schulte P.J., Lanas F., Gersh B.J., Hanna M., Pais P., Erol C., Diaz R., Bahit M.C., Bartunek J., De Caterina R., Goto S., Ruzyllo W., Zhu J., Granger C.B., Alexander J.H. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reductionin Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 2015; 132: 624 - 632..

34. Ezekowitz M.D., Nagarakanti R., Noack H., Brueckmann M., Litherland C., Jacobs M., Clemens A., Reilly P.A., Connolly S.J., Yusuf S., Wallentin L. Comparison of dabiga-tran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). Circulation 2016; 134: 589 - 598.

35. De Caterina R., Renda G., Carnicelli A.P., Nordio F., Trevisan M., Mercuri M.F., Ruff C.T., Antman E.M., Braunwald E., Giugliano R.P. Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol 2017; 69: 1372 - 1382.

36. Dunning J., Versteegh M., Fabbri A., Pavie A., Kolh P., Lockowandt U., Nashef S.A. EACTS Audit and Guidelines Committee. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg 2008; 34: 73 - 92.

37. Cannegieter S.C., Rosendaal F.R., Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994; 89: 635 - 641.

38. Heneghan C., Ward A., Perera R., Trialist C., Bankhead C., Fuller A., Stevens R., Bradford K., Tyndel S., Alonso-Coello P., Ansell J., Beyth R., Bernardo A., Christensen T.D., Cromheecke M.E., Edson R.G., Fitzmaurice D., Gadisseur A.P., Garcia-Alamino J.M., Gardiner C., Hasenkam J.M., Jacobson A., Kaatz S., Kamali F., Khan T.I., Knight E., Kortke H., Levi M., Matchar D., Menendez-Jandula B., Rakovac I., Schaefer C., Siebenhofer A., Souto J.C., Sunderji R., Gin K., Shalansky K., Voller H., Wagner O., Zittermann A. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012; 379: 322 - 334.

39. Brennan J.M., Edwards F.H., Zhao Y., O'Brien S., Booth M.E., Dokholyan R.S., Douglas P.S., Peterson E.D., DEcIDE AVR Research Team. Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac. Surgery National Database. J Am Coll Cardiol 2012; 60: 971 - 977.

40. Merie C., Kober L., Skov Olsen P., Andersson C., Gislason G., Skov Jensen J., Torp-Pedersen C. Association of warfarin therapy duration after bioprostheticaortic valve replacement with risk of mortality, thromboembolic complications and bleeding. JAMA 2012; 308: 2118 - 2125..

41. Christersson C., James S.K., Lindhagen L., Ahlsson A., Friberg O., Jeppsson A., Stahle E. Comparison of warfarin versus antiplatelet therapy after surgical bioprosthetic aortic valve replacement. Heart 2020;106:838 - 844.

42. Rafiq S., Steinbruchel D.A., Lilleor N.B., Moller C.H., Lund J.T., Thiis J.J., Kober L., Olsen P.S. Antithrombotic therapy after bioprosthetic aortic valve implantation: warfarin versus aspirin, a randomized controlled trial. Thromb Res 2017; 150: 104 - 110.

43. Massel D.R., Little S.H. Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev 2013: CD003464.

44. Hansen M.L., Sorensen R., Clausen M.T., Fog-Petersen M.L., Raunso J., Gadsboll N., Gislason G.H., Folke F., Andersen S.S., Schramm T.K., Abildstrom S.Z., Poulsen H.E., Kober L., Torp-Pedersen C. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170: 1433.

45. Fiedler K.A., Maeng M., Mehilli J., Schulz-Schupke S., Byrne R.A., Sibbing D., Hoppmann P., Schneider S., Fusaro M., Ott I., Kristensen S.D., Ibrahim T., Massberg S., Schunkert H., Laugwitz K.L., Kastrati A., Sarafoff N. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE Trial. J Am Coll Cardiol 2015; 65: 1619 - 1629.

46. Raffaele De Caterina, Stefan Agewall, Felicita Andreotti et all. Great Debate: Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week. European Heart Journal, Volume 43, Issue 37, 1 October 2022, Pages 3512 - 3527, https://doi.org/10.1093/eurheartj/ehac294.

47. Dewilde W.J., Oirbans T., Verheugt F.W., Kelder J.C., De Smet B.J., Herrman J.P., Adriaenssens T., Vrolix M., Heestermans A.A., Vis M.M., Tijsen J.G., van't Hof A.W., ten Berg J.M., WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking, oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381: 1107 - 1115.

48. Thourani V.H., Suri R.M., Gunter R.L., Sheng S., O'Brien S.M., Ailawadi G., Szeto W.Y., Dewey T.M., Guyton R.A., Bavaria J.E., Babaliaros V., Gammie J.S., Svensson L., Williams M., Badhwar V., Mack M.J. Contemporary real-world outcomes of surgical aortic valve replacement in 141,905 low-risk, intermediate-risk, and high-risk patients. Ann Thorac Surg 2015; 99: 55 - 61.

49. Reardon M.J., VanMieghem N.M., Popma J.J., Kleiman N.S., Sondergaard L., Mumtaz M., Adams D.H., Deeb G.M., Maini B., Gada H., Chetcuti S., Gleason T., Heiser J., Lange R., Merhi W., Oh J.K., SURTAVI Investigators. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 2017; 376: 1321 - 1331.

50. Zlotnick D.M., Ouellette M.L., Malenka D.J., De Simone J.P., Leavitt B.J., Helm R.E., Olmstead E.M., Costa S.P., DiScipio A.W., Likosky D.S., Schmoker J.D., Quinn R.D. Northern New England Cardiovascular Disease Study Group. Effect of preoperative pulmonary hypertension on outcomes in patients with severe aortic stenosis following surgical aortic valve replacement. Am J Cardiol 2013; 112: 1635 - 1640.

51. Mangner N., Stachel G., Woitek F., Haussig S., Schlotter F., Hollriegel R., Adam J., Lindner A., Mohr F.W., Schuler G., Kiefer P., Leontyev S., Borger M.A., Thiele H., Holzhey D., Linke A. Predictors of mortality and symptomatic outcome of patients with low-flow severe aortic stenosis undergoing transcatheter aortic valve replacement. J Am Heart Assoc 2018; 7: e007977.

52. Iung B., Laouenan C., Himbert D., Eltchaninoff H., Chevreul K., Donzeau-Gouge P., Fajadet J., Leprince P., Leguerrier A., Lievre M., Prat A., Teiger E., Laskar M., Vahanian A., Gilard M., FRANCE 2 Investigators. Predictive factors of early mortality after transcatheter aortic valve implantation: individual risk assessment using a simple score. Heart 2014; 100: 1016 - 1023.

53. Edwards F.H., Cohen D.J., O'Brien S.M., Peterson E.D., Mack M.J., Shahian D.M., Grover F.L., Tuzcu E.M., Thourani V.H., Carroll J., Brennan J.M., Brindis R.G., Rumsfeld J., Holmes D.R., Jr., Steering Committee of the Society of Thoracic Surgeons, American College of Cardiology Transcatheter Valve Therapy R. Development and validation of a risk prediction model for in-hospital mortality after transcatheter aortic valve replacement. JAMA Cardiol 2016; 1: 46 - 52.

54. Arnold S.V., Reynolds M.R., Lei Y., Magnuson E.A., Kirtane A.J., Kodali S.K., Zajarias A., Thourani V.H., Green P., Rodes-Cabau J., Beohar N., Mack M.J., Leon M.B., Cohen D.J., PARTNER Investigators. Predictors of poor outcomes after transcatheter aortic valve replacement: results from the PARTNER (Placement of Aortic Transcatheter Valve) trial. Circulation 2014; 129: 2682 - 2690.

55. Afilalo J. The Clinical Frailty Scale: Upgrade your eyeball test. Circulation 2017; 135: 2025 - 2027.

56. Kundi H., Popma J.J., Reynolds M.R., Strom J.B., Pinto D.S., Valsdottir L.R., Shen C., Choi E., Yeh R.W. Frailty and related outcomes in patients undergoing transcatheter valve therapies in a nationwide cohort. Eur Heart J 2019; 40: 2231 - 2239.

57. Hosler Q.P., Maltagliati A.J., Shi S.M., Afilalo J., Popma J.J., Khabbaz K.R., Laham R.J., Guibone K., Kim D.H. A practical two-stage frailty assessment for older adults undergoing aortic valve replacement. J Am Geriatr Soc 2019; 67: 2031 - 2037.

58. Dent E., Martin F.C., Bergman H., Woo J., Romero-Ortuno R., Walston J.D. Management of frailty: opportunities, challenges, and future directions. Lancet 2019; 394: 1376 - 1386.

59. Katz S. Assessing self-maintenance: activities of daily living, mobility, and instrumental activities of daily living. J Am Geriatr Soc 1983; 31: 721 - 727.

60. Steiner J.M., Cooper S., Kirkpatrick J.N. Palliative care in end-stage valvular heart disease. Heart 2017; 103: 1233 - 1237.

61. Deeb G.M., Reardon M.J., Chetcuti S., Patel H.J., Grossman P.M., Yakubov S.J., Kleiman N.S., Coselli J.S., Gleason T.G., Lee J.S., Hermiller J.B.Jr., Heiser J., Merhi W.,Zorn G.L., Tadros P., Robinson N., Petrossian G., Hughes G.C., Harrison J.K., Maini B., Mumtaz M., Conte J., Resar J., Aharonian V., Pfeffer T., Oh J.K., Qiao H., Adams D.H., Popma J.J., Core Valve US Clinical Investigators. 3-year outcomes in high-risk patients who underwent surgical or transcatheter aortic valve replacement. J Am Coll Cardiol 2016; 67: 2565 - 2574.

62. Lancellotti P., Magne J., Dulgheru R., Clavel M.A., Donal E., Vannan M.A., Chambers J., Rosenhek R., Habib G., Lloyd G., Nistri S., Garbi M., Marchetta S., Fattouch K., Coisne A., Montaigne D., Modine T., Davin L., Gach O., Radermecker M., Liu S., Gillam L., Rossi A., Galli E., Ilardi F., Tastet L., Capoulade R., Zilberszac R., Vollema E.M., Delgado V., Cosyns B., Lafitte S., Bernard A., Pierard L.A., Bax J.J., Pibarot P., Oury C. Outcomes of patients with asymptomatic aortic stenosis followed up in heart valve clinics. JAMA Cardiol 2018; 3: 1060 - 1068.

63. Dahl J.S., Eleid M.F., Michelena H.I., Scott C.G., Suri R.M., Schaff H.V., Pellikka P.A. Effect of left ventricular ejection fraction on postoperative outcome in patients with severe aortic stenosis undergoing aortic valve replacement. Circ Cardiovasc Imaging 2015; 8: e002917.

64. Taniguchi T., Morimoto T., Shiomi H., Ando K., Kanamori N., Murata K., Kitai T., Kadota K., Izumi C., Nakatsuma K., Sasa T., Watanabe H., Kuwabara Y., Makiyama T., Ono K., Shizuta S., Kato T., Saito N., Minatoya K., Kimura T., CURRENTAS Registry Investigators. Prognostic impact of left ventricular ejection fraction in patients with severe aortic stenosis. JACC Cardiovasc Interv 2018; 11: 145 - 157.

65. Bergler-Klein J., Klaar U., Heger M., Rosenhek R., Mundigler G., Gabriel H., Binder T., Pacher R., Maurer G., Baumgartner H. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 2004; 109: 2302 - 2308.

66. Bohbot Y., Kowalski C., Rusinaru D., Ringle A., Marechaux S., Tribouilloy C. Impact of mean transaortic pressure gradient on long-term outcome in patients with severe aortic stenosis and preserved left ventricular ejection fraction. J Am Heart Assoc 2017; 6.

67. Clavel M.A., Pibarot P., Messika-Zeitoun D., Capoulade R., Malouf J., Aggarval S., Araoz P.A., Michelena H.I., Cueff C., Larose E., Miller J.D., Vahanian A., Enriquez- Sarano M. Impact of aortic valve calcification, as measured by MDCT, on survival in patients with aortic stenosis: results of an international registry study. J Am Coll Cardiol 2014; 64: 1202 - 1213.

68. Pawade T., Clavel M.A., Tribouilloy C., Dreyfus J., Mathieu T., Tastet L., Renard C., Gun M., Jenkins W.S.A., Macron L., Sechrist J.W., Lacomis J.M., Nguyen V., Galian Gay L., Cuellar Calabria H., Ntalas I., Cartlidge T.R.G., Prendergast B., Rajani R., Evangelista A., Cavalcante J.L., Newby D.E., Pibarot P., Messika Zeitoun D., Dweck M.R. Computed tomography aortic valve calcium scoring in patients with aortic stenosis. Circ Cardiovasc Imaging 2018; 11: e007146.

69. Clavel M.A., Malouf J., Michelena H.I., Suri R.M., Jaffe A.S., Mahoney D.W., Enriquez- Sarano M. B-type natriuretic peptide clinical activation in aortic stenosis: impacton long-term survival. J Am Coll Cardiol 2014; 63: 2016 - 2025.

70. Nishimura R.A., O'Gara P.T., Bavaria J.E., Brindis R.G., Carroll J.D., Kavinsky C.J., Lindman B.R., Linderbaum J.A., Little S.H., Mack M.J., Mauri L., Miranda W.R., Shahian D.M., Sundt T.M. 2019 AATS/ACC/ASE/SCAI/STS Expert Consensus Systems of Care Document: a proposal to optimize care for patients with valvular heart disease: a joint report of the American Association for Thoracic Surgery, American College of Cardiology, American Society of Echocardiography, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2019; 73: 2609 - 2635.

71. Lindman B.R., Arnold S.V., Bagur R., Clarke L., Coylewright M., Evans F., Hung J., Lauck S.B., Peschin S., Sachdev V., Tate L.M., Wasfy J.H., Otto C.M. Priorities for patient-centered research in valvular heart disease: a report from the National Heart, Lung, and Blood Institute Working Group. J Am Heart Assoc 2020; 9: e015975.

72. Hejjaji V., Cohen D.J., Carroll J.D., Li Z., Manandhar P., Vemulapalli S., Nelson A.J., Malik A.O., Mack M.J., Spertus J.A., Arnold S.V. Practical application of patient-reported health status measures for transcatheter valve therapies: insights from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapies Registry. Circ Cardiovasc Qual Outcomes 2021; 14: e007187.

73. Goldstone A.B., Chiu P., Baiocchi M., Lingala B., Patrick W.L., Fischbein M.P., Woo Y.J. Mechanical or biologic prostheses for aortic-valve and mitral-valve replacement. N Engl J Med 2017; 377: 1847 - 1857.

74. Diaz R., Hernandez-Vaquero D., Alvarez-Cabo R., Avanzas P., Silva J., Moris C., Pascual I. Long-term outcomes of mechanical versus biological aortic valve prosthesis: systematic review and meta-analysis. J Thorac Cardiovasc Surg 2019; 158: 706 - 714.

75. Hammermeister K., Sethi G.K., Henderson W.G., Grover F.L., Oprian C., Rahimtoola S.H. Outcomes 15 years after valve replacement with a mechanicalversus a bioprosthetic valve: final report of the Veterans Affairs randomizedtrial. J Am CollCardiol 2000; 36: 1152 - 1158.

76. Oxenham H., Bloomfield P., Wheatley D.J., Lee R.J., Cunningham J., Prescott R.J., Miller H.C. Twenty year comparison of a Bjork-Shiley mechanical heart valvewith porcine bioprostheses. Heart 2003; 89: 715 - 721.

77. Stassano P., Di Tommaso L., Monaco M., Iorio F., Pepino P., Spampinato N., Vosa C. Aortic valve replacement: a prospective randomized evaluation of mechanicalversus biological valves in patients ages 55 to 70 years. J Am CollCardiol 2009; 54: 1862 - 1868.

78. Malik A.H., Yandrapalli S., Aronow W.S., Panza J.A., Cooper H.A. Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves. Heart 2019; 105: 1432 - 1436.

79. Duan L., Doctor J.N., Adams J.L., Romley J.A., Nguyen L.A., An J., Lee M.S.Comparison of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and bioprosthetic heart valves. Am J Cardiol 2021; 146: 22 - 28.

80. Pasciolla S., Zizza L.F., Le T., Wright K. Comparison of the efficacy and safety of direct oral anticoagulants and warfarin after bioprosthetic valve replacements. Clin Drug Investig 2020; 40: 839 - 845.

81. Russo V., Carbone A., Attena E., Rago A., Mazzone C., Proietti R., Parisi V., Scotti A., Nigro G., Golino P., D'Onofrio A. Clinical benefit of direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic heart valves. Clin Ther 2019; 41: 2549 - 2557.

82. Otto C.M, Mickel M.C., Kennedy J.W., et al. Three-year outcome after balloon aortic valvuloplasty: insights into prognosis of valvular aortic stenosis. Circulation 1994; 89: 642-50.

83. Lieberman E.B., Bashore T.M., Hermiller J.B., et al. Balloon aortic valvuloplasty in adults: failure of procedure to improve long-term survival. J Am Coll Cardiol 1995; 26: 1522 - 8.

84. Smith C.R., Leon M.B., Mack M.J., Miller D.C., Moses J.W., Svensson L.G., Tuzcu E.M., Webb J.G., Fontana G.P., Makkar R.R., Williams M., Dewey T., Kapadia S., Babaliaros V., Thourani V.H., Corso P., Pichard A.D., Bavaria J.E., Herrmann H.C., Akin J.J., Anderson W.N., Wang D., Pocock S.J., PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011; 364: 2187 - 2198.

85. Mack M.J., Leon M.B., Smith C.R., Miller D.C., Moses J.W., Tuzcu E.M., Webb J.G., Douglas P.S., Anderson W.N., Blackstone E.H., Kodali S.K., Makkar R.R., Fontana G.P., Kapadia S., Bavaria J., Hahn R.T., Thourani V.H., Babaliaros V., Pichard A., Herrmann H.C., Brown D.L., Williams M., Akin J., Davidson M.J., Svensson L.G., PARTNER 1 trial Investigators. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial, Lancet 2015; 385: 2477 - 2484.

86. Adams D.H., Popma J.J., Reardon M.J., Yakubov S.J., Coselli J.S., Deeb G.M., Gleason T.G., Buchbinder M., Hermiller J., Jr. Kleiman N.S,. Chetcuti S., Heiser J., Merhi W., Zorn G., Tadros P., Robinson N., Petrossian G., Hughes G.C., Harrison J.K., Conte J., Maini B., Mumtaz M., Chenoweth S., Oh J.K., Investigators USCC. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 2014; 370: 1790 - 1798.

87. Thyregod H.G., Steinbruchel D.A., Ihlemann N., Nissen H., Kjeldsen B.J., Petursson P., Chang Y., Franzen O.W., Engstrom T., Clemmensen P., Hansen P.B., Andersen L.W., Olsen P.S., Sondergaard L. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the All-Comers NOTION randomized clinical trial. J Am Coll Cardiol 2015; 65: 2184 - 2194.

88. Leon M.B., Smith C.R., Mack M.J., Makkar R.R., Svensson L.G., Kodali S.K., Thourani V.H., Tuzcu E.M., Miller D.C., Herrmann H.C., Doshi D., Cohen D.J., Pichard A.D., Kapadia S., Dewey T., Babaliaros V., Szeto W.Y., Williams M.R., Kereiakes D., Zajarias A., Greason K.L., Whisenant B.K., Hodson R.W., Moses J.W., Trento A., Brown D.L., Fearon W.F., Pibarot P., Hahn R.T., Jaber W.A., Anderson W.N., Alu M.C., Webb J.G., PARTNER 2, Investigators. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016; 374: 1609 - 1620.

89. Makkar R.R., Thourani V.H., Mack M.J., Kodali S.K., Kapadia S., Webb J.G., Yoon S.H., Trento A., Svensson L.G., Herrmann H.C., Szeto W.Y., Miller D.C., Satler L., Cohen D.J., Dewey T.M., Babaliaros V., Williams M.R., Kereiakes D.J., Zajarias A., Greason K.L., Whisenant B.K., Hodson R.W., Brown D.L., Fearon W.F., Russo M.J., Pibarot P., Hahn R.T., Jaber W.A., Rogers E., Xu K., Wheeler J., Alu M.C., Smith C.R., Leon M.B., Investigators P. Five-year outcomes of transcatheter or surgical aortic-valve replacement. N Engl J Med 2020; 382: 799 - 809.

90. Thyregod H.G.H., Ihlemann N., Jorgensen T.H., Nissen H., Kjeldsen B.J., Petursson P., Chang Y., Franzen O.W., Engstrom T., Clemmensen P., Hansen P.B., Andersen L.W., Steinbruchel D.A., Olsen P.S., Sondergaard L. Five-year clinical and echocardio- graphic outcomes from the Nordic Aortic Valve Intervention (NOTION) randomized clinical trial in lower surgical risk patients. Circulation 2019; 139: 2714 - 2723.

91. Siontis G.C., Praz F., Pilgrim T., Mavridis D., Verma S., Salanti G., Sondergaard L., Juni P., Windecker S. Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of severe aortic stenosis: a meta-analysis of randomized trials. Eur Heart J 2016; 37: 3503 - 3512.

92. Mack M.J., Leon M.B., Thourani V.H., Makkar R., Kodali S.K., Russo M., Kapadia S.R., Malaisrie S.C., Cohen D.J., Pibarot P., Leipsic J., Hahn R.T., Blanke P., Williams M.R., McCabe J.M., Brown D.L.,Babaliaros V., Goldman S., Szeto W.Y., Genereux P., Pershad A., Pocock S.J., Alu M.C., Webb J.G., Smith C.R., PARTNER 3 Investigators. Transcatheter aortic-valve replacement with a balloon-xpandable valve in low-risk patients. N Engl J Med 2019; 380: 1695 - 1705.

93. Popma J.J., Deeb G.M., Yakubov S.J., Mumtaz M., Gada H., O'Hair D., Bajwa T., Heiser J.C., Merhi W., Kleiman N.S., Askew J., Sorajja P., Rovin J., Chetcuti S.J., Adams D.H., Teirstein P.S., Zorn G.L., Forrest J.K., Tchetche D., Resar J., Walton A., Piazza N., Ramlawi B., Robinson N., Petrossian G., Gleason T.G., Oh J.K., Boulware M.J., Qiao H., Mugglin A.S., Reardon M.J., Evolut Low Risk Trial Investigators. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 2019; 380: 1706 - 1715.

94. Siontis G.C.M., Overtchouk P., Cahill T.J., Modine T., Prendergast B., Praz F., Pilgrim T., Petrinic T., Nikolakopoulou A., Salanti G., Sondergaard L., Verma S., Juni P., Windecker S. Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis. Eur Heart J 2019; 40: 3143 - 3153.

95. Leon M.B., Mack M.J., Hahn R.T., Thourani V.H., Makkar R., Kodali S.K., Alu M.C., Madhavan M.V., Chau K.H., Russo M., Kapadia S.R., Malaisrie S.C., Cohen D.J., Blanke P., Leipsic J.A., Williams M.R., McCabe J.M., Brown D.L., Babaliaros V., Goldman S., Herrmann H.C., Szeto W.Y., Genereux P., Pershad A., Lu M., Webb J.G., Smith C.R., Pibarot P., PARTNER 3 Investigators. Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk. J Am Coll Cardiol 2021; 77: 1149 - 1161.

96. Thourani V.H., Kodali S., Makkar R.R., Herrmann H.C., Williams M., Babaliaros V., Smalling R., Lim S., Malaisrie S.C., Kapadia S., Szeto W.Y., Greason K.L., Kereiakes D., Ailawadi G., Whisenant B.K., Devireddy C., Leipsic J., Hahn R.T., Pibarot P., Weissman N.J., Jaber W.A., Cohen D.J., Suri R., Tuzcu E.M., Svensson L.G., Webb J.G., Moses J.W., Mack M.J., Miller D.C., Smith C.R., Alu M.C., Parvataneni R., D'Agostino R.B., Jr., Leon M.B.., Mack M.J., Miller D.C., Smith C.R., Alu M.C., Parvataneni R., D'Agostino R.B., Jr., Leon M.B. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet 2016; 387: 2218 - 2225.

97. Gleason T.G., Reardon M.J., Popma J.J., Deeb G.M., Yakubov S.J., Lee J.S., Kleiman N.S., Chetcuti S., Hermiller J.B., Jr., Heiser J., Merhi W., Zorn G.L., Tadros P., Robinson N., Petrossian G., Hughes G.C., Harrison J.K., Conte J.V., Mumtaz M., Oh J.K., Huang J., Adams D.H., CoreValve US Pivotal High Risk Trial Clinical Investigators. 5-Year outcomes of self-expanding transcatheter versus surgical aortic valve replacement in high-risk patients. J Am Coll Cardiol 2018; 72: 2687 - 2696.

98. Leon M.B., Smith C.R., Mack M., Miller D.C., Moses J.W., Svensson L.G., Tuzcu E.M., Webb J.G., Fontana G.P., Makkar R.R., Brown D.L., Block P.C., Guyton R.A., Pichard A.D., Bavaria J.E., Herrmann H.C., Douglas P.S., Petersen J.L., Akin J.J., Anderson W.N., Wang D., Pocock S.; PARTNER Trial, PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010; 363: 1597 - 1607.

99. Vahanian A., Alfieri O., Al-Attar N., Antunes M., Bax J., Cormier B., Cribier A., De Jaegere P., Fournial G., Kappetein A.P., Kovac J., Ludgate S., Maisano F., Moat N., Mohr F. Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of, Percutaneous Cardiovascular Interventions (EAPCI) Eur Heart J. 2008; 29: 1463 - 1470.

100. Nashef S.A., Roques F., Michel P., Gauducheau E., Lemeshow S., Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999; 16: 9 - 13.

101. Kodali S.K., Williams M.R., Smith C.R., Svensson L.G., Webb J.G., Makkar R.R., Fontana G.P., Dewey T.M., Thourani V.H., Pichard A.D., Fischbein M., Szeto W.Y., Lim S., Greason K.L., Teirstein P.S., Malaisire S.C., Douglas P.S., Hahn R.T., Whisenant B., Zajarias A., Wang D., Akin J.J., Anderson W.N., and Leon M.B. for the PARTNER Trial Investogators. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012; 366: 1686-95.

102. Рыбка М.М., Хинчагов Д.Я., Мумладзе К.В., Никулкина Е.С. Под ред. Л.А. Бокерия. Протоколы анестезиологического обеспечения рентгенэндоваскулярных и диагностических процедур, выполняемых у кардиохирургических пациентов различных возрастных групп., Методические рекомендации. М.: НЦССХ им. А.Н. Бакулева РАМН; 2018.

103. Landoni G., et al. Volatile Anesthetics versus Total Intravenous Anesthesia for Cardiac Surgery// N Engl J Med. 2019. - Vol. 380(13). - Р. 1214 - 1225.

104. Sardo S., Osawa E.A., Finco G., Gomes Galas F.R.B., de Almeida J.P., Cutuli S.L., Frassanito C., Landoni G., Hajjar L.A. Nitric Oxide in Cardiac Surgery: A Meta-Analysis of Randomized Controlled Trials. J Cardiothorac Vasc Anesth. 2018 Dec; 32(6): 2512 - 2519. doi: 10.1053/j.jvca.2018.02.003.

105. Приказ Министерства здравоохранения РФ от 31 июля 2020 г. N 778н "О Порядке организации медицинской реабилитации взрослых" Зарегистрировано в Минюсте РФ 25 сентября 2020 г. Регистрационный N 60039 https://www.garant.ru/products/ipo/prime/doc/74581688.

106. Butchart E.G., Gohlke-BaЁrwolf C., Antunes M.J. Tornos P., De Caterina R., Cormier B., Prendergast B., Iung B. Recommendations for the management of patients after heart valve surgery. European Heart Journal (2005) 26, 2463 - 2471.

107. Ambrosetti M., Abreu A., , et al. Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. European Journal of Preventive Cardiology. 2021; 28: 460 - 495. doi: 10.1177/2047487320913379.

108. Eichler S., Salzwedel A., Reibis R., et al. Multicomponent cardiac rehabilitation in patients after transcatheter aortic valve implantation: Predictors of functional and psychocognitive recovery. Eur J Prev Cardiol. 2017; 24: 257 - 264. doi: 10.1177/2047487316679527.

109. Patrick D., Savage M.S., Jason L., et al. Cardiac Rehabilitation after Heart Valve Surgery: Comparison with Coronary Artery Bypass Grafting Patients. J Cardiopulm Rehabil Prev. 2015; 35(4): 231 - 237. doi:10.1097/HCR.0000000000000104.

110. Hansen T.B., Zwisler A.D., Berg S.K., et al. Cost-utility analysis of cardiac rehabilitation after conventional heart valve surgery versus usual care. Eur J Prev Cardiol. 2017; 24(7): 698 - 707. doi:10.1177/2047487317689908.

111. Gladkova M.A., Kassirsky G.I. Topical problems in rehabilitation following valve replacement. CorVasa. 1984; 26: 394 - 399.

112. Anderson L., Sharp G.A., Norton R.J., et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database of Systematic Reviews. 2017; 6: CD007130. doi: 10.1002/14651858.CD007130.

113. Thomas R.J., Beatty A.L., Beckle T.M., et al. Home-based cardiac rehabilitation: a scientific statement from the American Association of Cardiovascular and Pulmonary Rehabilitation, the American Heart Association, and the American College of Cardiology. Circulation. 2019; 140: e69 - e89. doi: 10.1161/CIR.0000000000000663.

114. Kraal J.J., Van den Akker-Van Marle M.E., Abu-Hanna A., et al. Clinical and cost-effectiveness of home-based cardiac rehabilitation compared to conventional, centre-based cardiac rehabilitation: results of the FIT@Home study. Eur J Prev Cardiol. 2017; 24(12): 1260 - 1273. doi: 10.1177/2047487317710803.

115. Федеральный закон от 29.07.2017 г. N 242-ФЗ "О внесении изменений в отдельные законодательные акты Российской Федерации по вопросам применения информационных технологий в сфере охраны здоровья" https://www.garant.ru/products/ipo/prime/doc/716328 44/.

116. Thomas R.J., Balady G., Banka G., et al. 2018 ACC/AHA Clinical Performance and Quality Measures for Cardiac Rehabilitation: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2018; 71(16): 1814 - 1837. doi: 10.1016/j.jacc.2018.01.004.

117. Иванова Г.Е., Мельникова Е.В., Шмонин А.А., Вербицкая Е.В., Аронов Д.М., Белкин А.А., Беляев А.Ф., Бодрова Р.А., Бубнова М.Г., Буйлова Т.В., Мальцева М.Н., Мишина И.Е., Нестерин К.В., Никифоров В.В., Прокопенко С.В., Сарана А.М., Стаховская Л.В., Суворов А, Хасанова Д.Р., Цыкунов М.Б. Применение международной классификации функционирования в процессе медицинской реабилитации. Вестник восстановительной медицины. 2018: (88): 2 - 77. eLIBRARY ID: 36486374.

118. https://www.icf-research-branch.org/download/send/12-cardiovascularandrespiratoryconditions/156-brief-icf-core-set-for-cardiopulmonary-conditions-in-acute-care.

119. https://www.icf-research-branch.org/download/send/12-cardiovascularandrespiratoryconditions/162-brief-icf-core-set-for-cardiopulmonary-conditions-in-post-acute-care.

120. Ambrosetti M., Abreu A., Cornelissen V., et al. Delphi consensus recommendations on how to provide cardiovascular rehabilitation in the COVID-19 era. Eur J Prev Cardiol. 2021; 28(5): 541 - 557. doi: 10.1093/eurjpc/zwaa080. PMID: 33624042.

121. Mezzani A., Hamm L.F., Jones A.M., et al. Aerobic exercise intensity assessment and prescription in cardiac rehabilitation: A joint position statement of the European association for cardiovascular prevention and rehabilitation, the American association of cardiovascular and pulmonary rehabilitation and the Canadian association of cardiac rehabilitation. Eur J Prev Cardiol. 2013; 20: 442 - 467. doi: 10.1177/2047487312460484.

122. Fletcher G.F., Ades P.A., Kligfield P., et al. Exercise Standards for Testing and Training A Scientific Statement From the American Heart Association. Circulation. 2013; 128: 873 - 934. doi: 10.1161/CIR.0b013e31829b5b44.

123. Opasich C., De Feo S., Pinna G.D., et al. Distance walked in the 6-minute test soon after cardiac surgery: toward an efficient use in the individual patient. Chest. 2004; 126(6): 1796 - 1801. doi: 10.1378/chest.126.6.1796.

124. Mok M., Nombela-Franco L., Urena M., et al. Prognostic value of exercise capacity as evaluated by the 6-minute walk test in patients undergoing transcatheter aortic valve implantation. J Am Coll Cardiol. 2013; 61(8): 897 - 898. doi: 10.1016/j.jacc.2012.10.050.

125. Nechwatal R.M. Cardiac rehabilitation after surgical and transcatheter valve replacement and repair. Dtsch Z Sportmed. 2018; 69: 285 - 292. doi: 10.5960/dzsm.2018.343.

126. Кардиология: национальное руководство: под ред. Е.В. Шляхто. 2-е изд., перераб. И доп. М.: ГЭОТАР-Медиа, 2015. 800 с.

127. Руководство по кардиологии: под ред. акад. Е.И. Чазова. В 4 т. М.: Издательский дом "Практика", 2014..

128. McMurray J.J.V., Solomon S.D., Inzucchi S.E., , Kosiborod M.N., Martinez F.A., Ponikowski P., Sabatine M.S., Anand I.S., , , Chiang C.-E., Chopra V.K., de Boer R.A., Desai A.S., Diez M., Drozdz J., , Ge J., Howlett J.G., Katova T., Kitakaze M., Ljungman C.E.A., Merkely B., Nicolau J.C., O'Meara E., Petrie M.C., Vinh P.N, Schou M., Tereshchenko S., Verma S., Held C., DeMets D.L., Docherty K.F., Jhund P.S., Bengtsson O., , Langkilde A.-M. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. September 19, 2019. doi: 10.1056/NEJMoa1911303.

129. Packer M., Anker S.D., Butler J., Filippatos G., Pocock S.J., Carson P., Januzzi J., Verma S., Tsutsui H., Brueckmann M., Jamal W., Kimura K., Schnee J., Zeller C., Cotton D., Bocchi E., Bohm M., Choi D.J., Chopra V., Chuquiure E., Giannetti N., Janssens S., Zhang J., Gonzalez Juanatey J.R., Kaul S., Brunner-La Rocca H.P., Merkely B., Nicholls S.J., Perrone S., Pina I., Ponikowski P., Sattar N., Senni M., Seronde M.F., Spinar J., Squire I., Taddei S., Wanner C., Zannad F., EMPERORReduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020; 383: 1413 - 1424.

130. Zannad F., Ferreira J.P., Pocock S.J., Anker S.D., Butler J., Filippatos G., Brueckmann M., Ofstad A.P., Pfarr E., Jamal W., Packer M. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254): 819 - 829. doi: 10.1016/S0140-6736(20)31824-9.

131. Zigmond A.S., Snaith R.P. The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica. 1983; 67 (6): 361 - 370. doi: 10.1111/j.16000447.1983.tb09716.x.

132. Mathias S., Nayak U.S., Isaacs B. Balance in elderly patients: the "get-up and go" test. Arch Phys Med Rehabil. 1986 Jun; 67(6): 387-9. PMID: 3487300.

133. Borg G.A. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982; 14: 377 - 381.

134. Borg G.A. Psychophysical scaling with applications in physical work and the perception of exertion. ScandJWorkEnvironHealth. 1990; 16 (Suppl 1): 55 - 58.

135. Иртюга О.Б., Жидулева Е.В., Муртазалиева П.М., и др. Патогенетические механизмы кальцификации аортального клапана: анализ собственных данных //Трансляционная медицина. - 2016. - Т. 3. - N. 1. - С. 21 - 28.

136. Irtyuga O., Malashicheva A., Zhiduleva E., et al. NOTCH1 Mutations in Aortic Stenosis: Association with Osteoprotegerin/RANK/RANKL. Biomed Res Int. 2017;2017:6917907. doi: 10.1155/2017/6917907

137. Иртюга О.Б., Жидулева Е.В., Муртазалиева П.М., и др. Роль системы остеопротегерина/RANKL/RANK в патогенезе аортального стеноза //Российский кардиологический журнал. - 2018. - N. 2. - С. 39 - 43.

138. Irtyuga O., Skitchenko R., Babakekhyan M., et al. The Role of NOTCH Pathway Genes in the Inherited Susceptibility to Aortic Stenosis. J Cardiovasc Dev Dis. 2024 Jul 17; 11(7): 226. doi: 10.3390/jcdd11070226.

139. Пугина М.Ю., Гареев Д.А., Коржова М.А., et al. Патоморфологические особенности осложнений у пациентов с бикуспидальным аортальным клапаном. Южно-Российский журнал терапевтической практики. 2023; 4(3): 62 - 69.

140. Irtyuga O., Kopanitsa G., Kostareva A., et al. Application of Machine Learning Methods to Analyze Occurrence and Clinical Features of Ascending Aortic Dilatation in Patients with and without Bicuspid Aortic Valve. J Pers Med. 2022; 12(5): 794. doi: 10.3390/jpm12050794.

141. Дроздов Д.В., Макаров Л.М., Баркан В.С., и др. Регистрация электрокардиограммы покоя в 12 общепринятых отведениях взрослым и детям 2023. Методические рекомендации. Российский кардиологический журнал. 2023; 28(10): 5631. doi: 10.15829/1560-4071-2023-5631.

142. Мацкеплишвили С.Т., Саидова М.А., Мироненко М.Ю., и др. Выполнение стандартной трансторакальной эхокардиографии. Методические рекомендации 2024. Российский кардиологический журнал. 2025; 30(2): 6271. https://doi.org/10.15829/1560-4071-2025-6271.

143. Демин А.А., Кобалава Ж.Д., Скопин И.И., и др. Инфекционный эндокардит и инфекция внутрисердечных устройств. Клинические рекомендации 2021. Российский кардиологический журнал. 2022; 27(10): 5233. https://doi.org/10.15829/1560-4071-2022-5233.

144. Кобалава Ж.Д., Конради А.О., Недогода С.В., и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2024. Российский кардиологический журнал. 2024; 29(9): 6117. https://doi.org/10.15829/1560-4071-2024-6117.

145. Ежов М.В., Кухарчук В.В., Сергиенко И.В., и др. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023; 28(5): 5471. https://doi.org/10.15829/1560-4071-2023-5471.

146. Галявич А.С., Терещенко С.Н., Ускач Т.М., и др. Хроническая сердечная недостаточность. Клинические рекомендации 2024. Российский кардиологический журнал. 2024; 29(11): 6162. https://doi.org/10.15829/1560-4071-2024-6162.

147. STS Short-term / Operative Risk Calculator Adult Cardiac Surgery Database - All Procedures https://acsdriskcalc.research.sts.org/

148. EuroSCORE is the world's best-known cardiac surgery risk stratification model https://euroscore.org/

149. Barili F., Pacini D., Capo A., Rasovic O., Grossi C., Alamanni F., et al. Does EuroSCORE II perform better than its original versions? A multicentre validation study. European heart journal. 2013; 34(1): 22-9.

150. Shahian D.M., Jacobs J.P., Badhwar V., Kurlansky P.A., Furnary A.P., Cleveland J.C., Jr., et al. The Society of Thoracic Surgeons 2018 adult cardiac surgery risk models: part 1-background, design considerations, and model development. The Annals of thoracic surgery. 2018; 105(5): 1411-8.

151. Kundi H., Popma J.J., Reynolds M.R., Strom J.B., Pinto D.S., Valsdottir L.R., et al. Frailty and related outcomes in patients undergoing transcatheter valve therapies in a nationwide cohort. European heart journal. 2019; 40(27): 2231-9.

152. Hosler Q.P., Maltagliati A.J., Shi S.M., Afilalo J., Popma J.J., Khabbaz K.R., et al. A practical two-stage frailty assessment for older adults undergoing aortic valve replacement. J Am Geriatr Soc. 2019; 67(10): 2031-7.

153. Dent E., Martin F.C., Bergman H., Woo J., Romero-Ortuno R., Walston J.D. Management of frailty: opportunities, challenges, and future directions. Lancet (London, England). 2019; 394(10206): 1376-86.

154. Goldfarb M., Lauck S., Webb J.G., Asgar A.W., Perrault L.P., Piazza N., et al. Malnutrition and mortality in frail and non-frail older adults undergoing aortic valve replacement. Circulation. 2018; 138(20): 2202-11.

155. Yanagisawa R., Tanaka M., Yashima F., Arai T., Kohno T., Shimizu H., et al. Frequency and consequences of cognitive impairment in patients underwent transcatheter aortic valve implantation. The American journal of cardiology. 2018; 122(5): 844-50.

156. Abramowitz Y., Kazuno Y., Chakravarty T., Kawamori H., Maeno Y., Anderson D., et al. Concomitant mitral annular calcification and severe aortic stenosis: prevalence, characteristics and outcome following transcatheter aortic valve replacement. European heart journal. 2017; 38(16): 1194-203.

157. Abramowitz Y., Jilaihawi H., Chakravarty T., Mack M.J., Makkar R.R. Porcelain aorta: a comprehensive review. Circulation. 2015; 131(9): 827-36.

158. Puri R., Iung B., Cohen D.J., TAVI or No TAVI: identifying patients unlikely to benefit from transcatheter aortic valve implantation. European heart journal. 2016; 37(28): 2217-25.

159. Gunter R.L., Kilgo P., Guyton R.A., Chen E.P., Puskas J.D., Cooper W.A., et al. Impact of preoperative chronic lung disease on survival after surgical aortic valve replacement. The Annals of thoracic surgery. 2013; 96(4): 1322-8.

160. Allende R., Webb J.G., Munoz-Garcia A.J., de Jaegere P., Tamburino C., Dager A.E., et al. Advanced chronic kidney disease in patients undergoing transcatheter aortic valve implantation: insights on clinical outcomes and prognostic markers from a large cohort of patients. European heart journal. 2014; 35(38): 2685-96.

161. Tirado-Conte G., ., ., Barbanti M., Lhermusier T., Amat-Santos I., et al. Clinical outcomes and prognosis markers of patients with liver disease undergoing transcatheter aortic valve replacement: a propensity score-matched analysis. Circ Cardiovasc Interv. 2018; 11(3): e005727.

162. Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., ., et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European heart journal. 2020; 42(5): 373 - 498.

163. Tsai Y.C., Phan K., Munkholm-Larsen S., Tian D.H., La Meir M., Yan T.D.. Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation: a meta-analysis. European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery. 2015; 47(5): 847-54.

164. Yao X., Gersh B.J., Holmes D.R., Jr., Melduni R.M., Johnsrud D.O., Sangaralingham L.R., et al. Association of surgical left atrial appendage occlusion with subsequent stroke and mortality among patients undergoing cardiac surgery. Jama. 2018; 319(20): 2116-26.

165. ., ., Gualis J., ., Maiorano P., Castillo L., et al. Beneficial effect of left atrial appendage closure during cardiac surgery: a meta-analysis of 280 585 patients. European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery. 2020; 57(2): 252-62.

166. Gropper M.A., Miller R.D., Eriksson L.I., Fleisher L.A., Wiener-Kronish J.P., Cohen L.H., et al. (7 October 2019). Miller's Anesthesia (9th ed.). Philadelphia, PA: Elsevier. ISBN 978-0-323-61264-7.

167. , Ahmet et al. "Vaccination of adults with heart failure and chronic heart conditions: Expert opinion." Turk Kardiyoloji Dernegi arsivi: Turk Kardiyoloji Derneginin yayin organidir vol. 46,8 (2018): 723 - 734. doi: 10.5543/tkda.2018.10.5543/tkda.2018.37048

168. Аверков О.В., Арутюнян Г.К., Дупляков Д.В., и др. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2024. Российский кардиологический журнал. 2025; 30(3): 6306. https://doi.org/10.15829/1560-4071-2025-6306.

169. Барбараш О.Л., Карпов Ю.А., Панов А.В., и др. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2024. Российский кардиологический журнал. 2024; 29(9): 6110.

170. Комлев А.Е., Саидова М.А., Имаев Т.Э., Шитов В.Н., Акчурин Р.С.. Гемодинамические варианты тяжелого аортального стеноза / Рациональная фармакотерапия в кардиологии. - 2020. - Т. 16, N 5. - С. 822 - 830.

171. Мкртычев Д.С., Комлев А.Е., Колегаев А.С., Лепилин П.М., Кучин И.В., Саличкин Д.В., Имаев Т.Э. Транскатетерное протезирование у пациентов с истинным бикуспидальным клапаном. Кардиология и сердечно-сосудистая хирургия. - 2024. - Т. 17, N 3. - С. 306 - 312.

172. Neumann F.J., Sousa-Uva M., Ahlsson A., Alfonso F., Banning A.P., Benedetto U., Byrne R.A., Collet J.P., Falk V., Head S.J., ., Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019 Jan 7; 40(2): 87 - 165.

173. Teitelbaum M., Kotronias R.A., Sposato L.A., Bagur R. Cerebral Embolic Protection in TAVI: Friend or Foe. Interv Cardiol. 2019 Feb; 14(1): 22 - 25.

174. Kharbanda R.K., Perkins A.D., Kennedy J., Banning A.P., Baumbach A., Blackman D.J., Dodd M., Evans R., Hildick-Smith D., Jamal Z., Ludman P., Palmer S., Stables R., Clayton T.. Routine cerebral embolic protection in transcatheter aortic valve implantation: rationale and design of the randomised British Heart Foundation PROTECT-TAVI trial. EuroIntervention. 2023 Apr 24; 18(17): 1428 - 1435.

175. Balata M., Gbreel M.I., Elkasaby M.H., Badran A.S., Hassan M., Westenfeld R., Pfister R., Zimmer S., Becher M.U., Nickenig G., Sugiura A. Cerebral embolic protection in transcatheter aortic valve implantation (TAVI): a pooled analysis of 4091 patients. Cardiovasc Interv Ther. 2025 Jul; 40(3): 490 - 505.

176. Praz, F., Borger, M.A., Lanz, J., et al. ESC/EACTS Scientific Document Group (2025). 2025 ESC/EACTS Guidelines for the management of valvular heart disease. European heart journal, ehaf194. Advance online publication. https://doi.org/10.1093/eurheartj/ehaf194.

177. , Sabahattin et al. "Sixty-Four-Section Cardiac Computed Tomography in Mechanical Prosthetic Heart Valve Dysfunction: Thrombus or Pannus." Circulation. Cardiovascular imaging vol. 8, 12 (2015): e003246. doi: 10.1161/CIRCIMAGING.115.003246.

178. Chakravarty, Tarun et al. "Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study." Lancet (London, England) vol. 389,10087 (2017): 2383 - 2392. doi: 10.1016/S0140-6736(17) 30757-2.

179. Jiang, Yefan et al. "Mechanical versus Bioprosthetic Aortic Valve Replacement in Middle-Aged Adults: A Systematic Review and Meta-Analysis." Journal of cardiovascular development and disease vol. 10,2 90. 20 Feb. 2023, doi: 10.3390/jcdd10020090.

180. Tasoudis, Panagiotis T et al. "Mechanical versus bioprosthetic valve for aortic valve replacement: systematic review and meta-analysis of reconstructed individual participant data." European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracic Surgery vol. 62,1 (2022): ezac268. doi: 10.1093/ejcts/ezac268.

181. Leviner, Dror B et al. "Mechanical vs Bioprosthetic Aortic Valve Replacement in Patients Younger Than 70 Years of Age: A Hazard Ratio Meta-analysis." The Canadian journal of cardiology vol. 38,3 (2022): 355 - 364. doi: 10.1016/j.cjca.2021.12.008.

182. Gatti M., Gallone G., Poggi V., Bruno F., Serafini A., Depaoli A., et al. Diagnostic accuracy of coronary computed tomography angiography for the evaluation of obstructive coronary artery disease in patients referred for transcatheter aortic valve implantation: a sys tematic review and meta-analysis. Eur Radiol 2022; 32: 5189-200. https://doi.org/10.1007/s00330-022-08603-y.

183. Diller G.P., Gerwing M., Boroni Grazioli S., De-Torres-Alba F., Radke R.M., Vormbrock J., et al. Utility of coronary computed tomography angiography in patients undergoing transcatheter aortic valve implantation: a meta-analysis and meta-regression based on published data from 7458 patients. J Clin Med 2024; 13: 631. https://doi.org/10.3390/jcm13020631.

184. Kondoleon N.P., Layoun H., Spilias N., Sipko J., Kanaan C., Harb S., et al. Effectiveness of pre-TAVR CTA as a screening tool for significant CAD before TAVR. JACC Cardiovasc Interv 2023; 16: 1990 - 2000. https://doi.org/10.1016/j.jcin.2023.05.030.

185. Malebranche D., Hoffner M.K.M., Huber A.T., Cicovic A., Spano G., Bernhard B., et al. Diagnostic performance of quantitative coronary artery disease assessment using computed tomography in patients with aortic stenosis undergoing transcatheter aortic-valve implantation. BMC Cardiovasc Disord 2022; 22: 178. https://doi.org/10.1186/s12872-022-02623-8.

186. Chieffo A., Giustino G., Spagnolo P., Panoulas V.F., Montorfano M., Latib A., et al. Routine screening of coronary artery disease with computed tomographic coronary angiography in place of invasive coronary angiography in patients undergoing transcatheter aortic valve replacement. Circ Cardiovasc Interv 2015; 8: e002025. https://doi.org/10.1161/circinterventions.114.002025.

187. Иртюга О.Б., Ляпина И.Н., Воробьева Н.А., и др. Ключевые аспекты организации работы школы для пациентов, принимающих антагонисты витамина К. Согласованное мнение экспертов Российский кардиологический журнал 2025; 30(9): 6529. doi: 10.15829/1560-4071-2025-6529 ISSN 1560 - 4071.

188. Hanigan S., Kong X., Haymart B., Kline-Rogers E., Kaatz S., Krol G., et al. Standard versus higher intensity anticoagulation for patients with mechanical aortic valve replacement and additional risk factors for thromboembolism. Am J Cardiol 2021; 159: 100-6. https://doi.org/10.1016/j.amjcard.2021.08.023.

189. Puskas J., Gerdisch M., Nichols D., Quinn R., Anderson C., Rhenman B., et al. Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized On-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. J Thorac Cardiovasc Surg 2014; 147: 1202-10; discussion 1210-1201. https://doi.org/10.1016/j.jtcvs.2014.01.004.

190. Engelen E.T., Schutgens R.E., Mauser-Bunschoten E.P., van Es RJJ, van Galen KPM. Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants under going minor oral surgery or dental extractions. Cochrane Database Syst Rev 2018; 7: CD012293. https://doi.org/10.1002/14651858.CD012293.pub2.

191. Makuloluwa A.K., Tiew S., Briggs M. Peri-operative management of ophthalmic patients on anti-thrombotic agents: a literature review. Eye (Lond) 2019; 33: 1044-59. https://doi.org/10.1038/s41433-019-0382-6.

192. Nagata N., Yasunaga H., Matsui H., Fushimi K., Watanabe K., Akiyama J., et al. Therapeutic endoscopy-related GI bleeding and thromboembolic events in patients using warfarin or direct oral anticoagulants: results from a large nationwide database analysis. Gut 2018;67:1805-12. https://doi.org/10.1136/gutjnl-2017-313999.

193. Dohler I., Roder D., Schlesinger T., Nassen C.A., Germer C.T., Wiegering A., et al. Risk-adjusted perioperative bridging anticoagulation reduces bleeding complications without increasing thromboembolic events in general and visceral surgery. BMC Anesthesiol 2023; 23: 56. https://doi.org/10.1186/s12871-023-02017-z.

194. Shah S., Nayfeh T., Hasan B., Urtecho M., Firwana M., Saadi S., et al. Perioperative man agement of vitamin K antagonists and direct oral anticoagulants: a systematic review and meta-analysis. Chest 2023; 163: 1245-57. https://doi.org/10.1016/j.chest.2022.11.032

195. Kovacs M.J., Wells P.S., Anderson D.R., Lazo-Langner A., Kearon C., Bates S.M., et al. Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial. BMJ 2021; 373: n1205. https://doi.org/10.1136/bmj.n1205.

196. Kuo H.C., Liu F.L., Chen J.T., Cherng Y.G., Tam K.W., Tai Y.H. Thromboembolic and bleed ing risk of periprocedural bridging anticoagulation: a systematic review and meta-analysis. Clin Cardiol 2020; 43: 441-9. https://doi.org/10.1002/clc.23336.

197. Brouwer J., Nijenhuis V.J., Delewi R., Hermanides R.S., Holvoet W., Dubois C.L.F., et al. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation. N Engl J Med 2020; 383: 1447-57. https://doi.org/10.1056/NEJMoa2017815.